A functional test for homologous recombination deficiency validated across laboratories
Tests for 'HRD', which decide who gets PARP inhibitors, rely on genomic scars that reflect the tumour's past, not its present. A test of current DNA-repair function would be better, but needs standardising.
Genomic scar assays (for example the Myriad myChoice score) predict PARP inhibitor benefit imperfectly and remain positive after resistance develops. Functional assays (RAD51 foci formation on tissue) measure current repair capacity and have shown promise in retrospective series. A consortium to standardise the RAD51 assay (antibodies, scoring, reference tissue) and validate it prospectively in a PARP inhibitor trial would give a dynamic, mechanism-based biomarker.
- Biomarkers are not validated or standardised · Tests that decide who gets a drug are often not validated prospectively and are measured differently in every lab.
Pages like this
not linked directly; found by shared links- TrialSOLO-1
Shares PARP inhibitors, Olaparib, PARP, BRCA1 / BRCA2 (HRD).
- PersonAlan Ashworth
Shares PARP inhibitors, Olaparib, PARP, BRCA1 / BRCA2 (HRD).
- TrialPOLO
Shares PARP inhibitors, Olaparib, PARP, BRCA1 / BRCA2 (HRD).
- Key paperPAOLA-1: olaparib added to bevacizumab maintenance in newly diagnosed ovarian cancer, with benefit confined to HRD-positive tumours
Shares HRD & BRCA testing, Homologous recombination deficiency (HRD), PARP inhibitors, Olaparib.
- TrialPAOLA-1 / ENGOT-ov25
Shares Homologous recombination deficiency (HRD), Olaparib, PARP, BRCA1 / BRCA2 (HRD).
- PairingPARP inhibitor + bevacizumab maintenance (HRD-positive)
Shares Homologous recombination deficiency (HRD), Olaparib, PARP, Ovarian cancer.
- ProductRucaparib
Shares Homologous recombination deficiency (HRD), PARP inhibitors, PARP, BRCA1 / BRCA2 (HRD).
- CollectionOvarian Cancer Research Alliance (OCRA)
Shares Homologous recombination deficiency (HRD), PARP inhibitors, BRCA1 / BRCA2 (HRD), Ovarian cancer.